Modeling human osteosarcoma in mice through 3AB-OS cancer stem cell xenografts

Journal of Cellular Biochemistry

Volumn 113, Issue 11, 2012, Pages 3380-3392

  Di Fiore, Riccardo ^a   Guercio, Annalisa ^b   Puleio, Roberto ^b   Di Marco, Patrizia ^b   Drago Ferrante, Rosa ^a   D'Anneo, Antonella ^a   De Blasio, Anna ^a   Carlisi, Daniela ^a   Di Bella, Santina ^a   Pentimalli, Francesca ^c   Forte, Iris M ^c   Giordano, Antonio ^c,d,e   Tesoriere, Giovanni ^a   Vento, Renza ^a,d  

^a UNIVERSITY OF PALERMO   (Italy)

^b ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELLA SICILIA A MIRRI   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d Temple University   (United States)

^e UNIVERSITY OF SIENA   (Italy)

Author keywords

3AB OS CSCS; ANIMAL MODELS; MATRIGEL; OSTEOSARCOMA; XENOGRAFT

Indexed keywords

APC PROTEIN; BETA CATENIN; BETA1 INTEGRIN; CYCLIN D2; FOCAL ADHESION KINASE; GLYCOGEN SYNTHASE KINASE 3BETA; MATRIGEL; MYC PROTEIN; PROTEIN BCL 2; PROTEIN KINASE B; RETINOBLASTOMA PROTEIN; UVOMORULIN; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER STEM CELL; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GROWTH RATE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; OSTEOSARCOMA; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR ENGRAFTMENT; TUMOR XENOGRAFT;

ANIMALS; BONE NEOPLASMS; COLLAGEN; DRUG COMBINATIONS; FOCAL ADHESION KINASE 1; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INJECTIONS, SUBCUTANEOUS; INTEGRIN BETA CHAINS; LAMININ; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; OSTEOSARCOMA; PLURIPOTENT STEM CELLS; PROTEOGLYCANS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL;

MUS;

EID: 84866514097     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24214     Document Type: Article

References (36)

1. Céspedes MV, Casanova I, Parreño M, Mangues R,. 2006. Mouse models in oncogenesis and cancer therapy. Clin Transl Oncol 8: 318-329.
2. Chen L, Daley GQ,. 2008. Molecular basis of pluripotency. Hum Mol Genet 17 (R1): R23-R27.
3. Clevers H,. 2011. The cancer stem cell: Premises, promises and challenges. Nat Med 17: 313-319.
4. Coffer PJ, Burgering BM,. 2004. Forkhead-box transcription factors and their role in the immune system. Nat Rev Immunol 4: 889-899.
5. Cox JL, Rizzino A,. 2010. Induced pluripotent stem cells: What lies beyond the paradigm shift. Exp Biol Med 235: 148-158.
6. Dick FA,. 2007. Structure-function analysis of the retinoblastoma tumor suppressor protein-is the whole a sum of its parts ? Cell Div 13 (2): 26.
7. Di Fiore R, Santulli A, Ferrante RD, Giuliano M, De Blasio A, Messina C, Pirozzi G, Tirino V, Tesoriere G, Vento R,. 2009. Identification and expansion of human osteosarcoma-cancer-stem cells by long-term 3-aminobenzamide treatment. J Cell Physiol 219: 301-313.
8. Euhus DM, Hudd C, LaRegina MC, Johnson FE,. 1986. Tumor measurement in the nude mouse. J Surg Oncol 31: 229-234.
9. Fang D, Hawke D, Zheng Y, Xia Y, Meisenhelder J, Nika H, Mills GB, Kobayashi R, Hunter T, Lu Z,. 2007. Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem 282: 11221-11229.
10. Giordano A, Fucito A, Romano G, Marino IR,. 2007. Carcinogenesis and environment: The cancer stem cell hypothesis and implications for the development of novel therapeutics and diagnostics. Front Biosci 12: 3475-3482.
11. Gisselsson D,. 2011. Intratumor diversity and clonal evolution in cancer-a skeptical standpoint. Adv Cancer Res 112: 1-9.
12. Han JW, Lee HJ, Bae GU, Kang JS,. 2011. Promyogenic function of Integrin/FAK signaling is mediated by Cdo, Cdc42 and MyoD. Cell Signal 23: 1162-1169.
13. Jeanes A, Gottardi CJ, Yap AS,. 2008. Cadherins and cancer: How does cadherin dysfunction promote tumor progression ? Oncogene. 27: 6920-6929.
14. Kalluri R, Weinberg RA,. 2009. The basics of epithelial-mesenchymal transition. J Clin Invest 119: 1420-1428.
15. Kitzmann M, Fernandez A,. 2001. Crosstalk between cell cycle regulators and the myogenic factor MyoD in skeletal myoblasts. Cell Mol Life Sci 58: 571-579.
16. Li L, Neaves WB,. 2006. Normal stem cells and cancer stem cells: The niche matters. Cancer Res 66: 4553-4557.
17. MacDonald BT, Tamai K, He X,. 2009. Wnt/beta-catenin signaling: Components, mechanisms, and diseases. Dev Cell 17: 9-26.
18. Maitland NJ, Collins AT,. 2008. Prostate cancer stem cells: A new target for therapy. J Clin Oncol 26: 2862-2870.
19. Markiewicz E, Ledran M, Hutchison CJ,. 2005. Remodelling of the nuclear lamina and nucleoskeleton is required for skeletal muscle differentiation in vitro. J Cell Sci 118: 409-420.
20. Meng X, Neises A, Su RJ, Payne KJ, Ritter L, Gridley DS, Wang J, Sheng M, William Lau KH, Baylink DJ, Zhang XB,. 2012. Efficient reprogramming of human cord blood CD34+ cells into induced pluripotent stem cells with OCT4 and SOX2 alone. Mol Ther 20: 408-416.
21. Mohamet L, Hawkins K, Ward CM,. 2011. Loss of function of E-cadherin in embryonic stem cells and the relevance to models of tumorigenesis. J Oncol 2011: 352616.
22. Muskhelishvili L, Latendresse JR, Kodell RL, Henderson EB,. 2003. Evaluation of cell proliferation in rat tissues with BrdU, PCNA, Ki-67(MIB-5) immunohistochemistry and in situ hybridization for histone mRNA. J Histochem Cytochem 51: 1681-1688.
23. Nehls M, Kyewski B, Messerle M, Waldschütz R, Schüddekopf K, Smith AJ, Boehm T,. 1996. Two genetically separable steps in the differentiation of thymic epithelium. Science 272: 886-889.
24. Ponce DP, Maturana JL, Cabello P, Yefi R, Niechi I, Silva E, Armisen R, Galindo M, Antonelli M, Tapia JC,. 2011. Phosphorylation of AKT/PKB by CK2 is necessary for the AKT-dependent up-regulation of beta-catenin transcriptional activity. J Cell Physiol 226: 1953-1959.
25. Sharkey FE, Fogh J,. 1984. Considerations in the use of nude mice for cancer research. Cancer Metastasis Rev 3: 341-360.
26. Siclari VA, Qin L,. 2010. Targeting the osteosarcoma cancer stem cell. J Orthop Surg Res 5: 78.
27. Smida J, Baumhoer D, Rosemann M, Walch A, Bielack S, Poremba C, Remberger K, Korsching E, Scheurlen W, Dierkes C, Burdach S, Jundt G, Atkinson MJ, Nathrath M,. 2010. Genomic alterations and allelic imbalances are strong prognostic predictors in osteosarcoma. Clin Cancer Res 16: 4256-4267.
28. Sun L, Liu L, Yang XJ, Wu Z,. 2004. Akt binds prohibitin 2 and relieves its repression of MyoD and muscle differentiation. J Cell Sci 117: 3021-3029.
29. Ta HT, Dass CR, Choong PF, Dunstan DE,. 2009. Osteosarcoma treatment: State of the art. Cancer Metastasis Rev 28: 247-263.
30. Tian Q, Feetham MC, Tao WA, He XC, Li L, Aebersold R, Hood L,. 2004. Proteomic analysis identifies that 14-3-3zeta interacts with beta-catenin and facilitates its activation by Akt. Proc Natl Acad Sci USA 101: 15370-15375.
31. Tomayko MM, Reynolds CP,. 1989. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother. Pharmacol 24: 148-154.
32. Topley P, Jenkins DC, Jessup EA, Stables JN,. 1993. Effect of reconstituted basement membrane components on the growth of a panel of human tumour cell lines in nude mice. Br J Cancer 67: 953-958.
33. Troiani T, Schettino C, Martinelli E, Morgillo F, Tortora G, Ciardiello F,. 2008. The use of xenograft models for the selection of cancer treatments with the EGFR as an example. Crit Rev Oncol Hematol 65: 200-211.
34. Ullman-Culleré MH, Foltz CJ,. 1999. Body condition scoring: A rapid and accurate method for assessing health status in mice. Lab Anim Sci 49: 319-323.
35. Wesolowski R, Budd GT,. 2010. Use of chemotherapy for patients with bone and soft-tissue sarcomas. Cleve Clin J Med 77: S23-S26.
36. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA,. 2007. Induced pluripotent stem cell lines derived from Human Somatic Cells. Science 318: 1917-1920.